{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:26:17Z","timestamp":1784204777681,"version":"3.55.0"},"reference-count":23,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Farma S.p.A."},{"name":"CliCon S.r.l. Societ\u00e0 Benefit"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Real world data are becoming a crucial tool to understand how cancer is treated in routine daily practice. This real-world analysis aims to describe the characteristics of patients with CML in 2nd or \u22653rd tyrosine kinase inhibitors (TKI) lines of therapy, to evaluate their treatment sequence and utilization in settings of Italian clinical practice in Italy. A retrospective analysis was performed using an administrative databases covering around 15.3 million cases. All adult patients prescribed with TKI as 2nd or \u22653rd lines (L) of therapy for CML during January 2015\u2013December 2018 were included. A total of 491 patients in 2nd and 144 in \u22653rd L was included. In both cohorts, hypertension was the most reported comorbidity, followed by metabolic and blood count alterations. In each calendar inclusion year, an increment of 97.6% was observed in the number of patients treated in \u22653rd L. In the 2nd L cohort, 18.7% had a switch to 3rd L, while 26.4% of \u22653rd L patients switched to a subsequent line. Around 40% in both lines discontinued their treatment after a median time of 5.5 (2nd L) and 4.3 (\u22653rd L) years. The results provided insights into CML management clinical practice, indicating a heavy disease burden for patients in later lines that showed an increasing complex management, and suggest that a need for novel treatment strategies might exists.<\/jats:p>","DOI":"10.3390\/jcm11133597","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:31:06Z","timestamp":1655933466000},"page":"3597","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Sapienza University Policlinico Umberto I, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Chiodi","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A., 21042 Origgio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio Pio","family":"Nardozza","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A., 21042 Origgio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Valsecchi","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A., 21042 Origgio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[{"name":"CliCon S.R.L. Societ\u00e0 Benefit, 40137 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Sangiorgi","sequence":"additional","affiliation":[{"name":"CliCon S.R.L. Societ\u00e0 Benefit, 40137 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giacomini","sequence":"additional","affiliation":[{"name":"CliCon S.R.L. Societ\u00e0 Benefit, 40137 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Rendace","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A., 21042 Origgio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Coco","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A., 21042 Origgio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Premoli","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A., 21042 Origgio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[{"name":"CliCon S.R.L. Societ\u00e0 Benefit, 40137 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_2","unstructured":"Eden, R.E., and Coviello, J.M. (2021). Chronic Myelogenous Leukemia. StatPearls, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-World Evidence in Oncology: Opportunities and Limitations","volume":"25","author":"Perrone","year":"2020","journal-title":"Oncologist"},{"key":"ref_5","unstructured":"Jain, P., Kantarjian, H., Alattar, M.L., Jabbour, E., Sasaki, K., Gonzalez, G.N., Dellasala, S., Pierce, S., Verstovsek, S., and Wierda, W. (2022, June 21). Analysis of Long Term Responses and Their Impact on Outcomes in Patients with Chronic Phase CML Treated with Four Different TKI Modalities\u2014Analysis of 5 Prospective Clinical Trials, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4854752\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic Factors and Survival Outcomes in Patients with Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"ref_7","unstructured":"Jain, P., Kantarjian, H., Alattar, M.L., Jabbour, E., Sasaki, K., Nogueras Gonzalez, G., Dellasala, S., Pierce, S., Verstovsek, S., and Wierda, W. (2022, June 21). Long-Term Molecular and Cytogenetic Response and Survival Outcomes with Imatinib 400 Mg, Imatinib 800 Mg, Dasatinib, and Nilotinib in Patients with Chronic-Phase Chronic Myeloid Leukaemia: Retrospective Analysis of Patient Data from Five Clinical Trials. Available online: https:\/\/www.thelancet.com\/journals\/lanhae\/article\/PIIS2352-3026(15)00021-6\/fulltext."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fonc.2020.00883","article-title":"Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia","volume":"10","author":"Annunziata","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing Chronic Myeloid Leukemia for Treatment-Free Remission: A Proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-World Data: Towards Achieving the Achievable in Cancer Care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-Line Therapy for Chronic Myeloid Leukemia: Current Status and Future Directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.2217\/fon-2019-0555","article-title":"The Role of Bosutinib in the Treatment of Chronic Myeloid Leukemia","volume":"16","author":"Coutre","year":"2020","journal-title":"Future Oncol."},{"key":"ref_13","unstructured":"Gruppo Italiano Malattie EMatologiche dell\u2019Adulto (2022, June 21). Bosutinib Efficacy, Safety, Tolerability (BEST) Study in Elderly Chronic Myeloid Leukemia Patients Failing Front.-Line Treatment With Other Tyrosine Kinase Inhibitors, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02810990."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood-2019-127029","article-title":"Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant\/Intolerant to Frontline Tyrosine-Kynase Inhibitors","volume":"134","author":"Latagliata","year":"2019","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2019.7303","article-title":"Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML","volume":"17","author":"Banegas","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.16733","article-title":"Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: The UK TARGET CML study","volume":"192","author":"Milojkovic","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood-2021-148773","article-title":"Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence","volume":"138","author":"Dahlen","year":"2021","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib Discontinuation in Chronic Myeloid Leukaemia Patients with Undetectable BCR-ABL Transcript Level: A Systematic Review and a Meta-Analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: Primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood.V126.23.4051.4051","article-title":"Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia","volume":"126","author":"Lomaia","year":"2015","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: When and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.jval.2021.04.321","article-title":"PCN231 Humanistic and Economic Burden in Patients with Chronic Myeloid Leukemia \u00c2\u2013A Review of the Literature","volume":"24","author":"Negi","year":"2021","journal-title":"Value Health"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/13\/3597\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:37:34Z","timestamp":1760139454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/13\/3597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":23,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcm11133597"],"URL":"https:\/\/doi.org\/10.3390\/jcm11133597","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}